WORCESTER, Mass., Sept. 7, 2011 (GLOBE NEWSWIRE) -- RXi Pharmaceuticals Corporation (Nasdaq:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, today announced that new preclinical data using proprietary self-delivering RNAi (sd-rxRNA™) compounds, including RXI-109, will be presented at the 7th Annual Meeting of the Oligonucleotide Therapeutics Society, September 8-10, 2011 in Copenhagen, Denmark.
